黏蛋白阿克曼菌辅助治疗恶性肿瘤的研究进展

Akkermansia muciniphila in adjuvant treatment of malignant tumors

摘要:

恶性肿瘤是威胁人类健康的全球重大公共卫生问题，多种方法联合，特别是以靶向治疗联合免疫治疗为主的治疗手段，在一定程度延缓了恶性肿瘤的发展，提高了患者的近期生存率，但这些治疗方法并不能覆盖所有患者，远期疗效仍然有限。因此，如何提高患者的生存质量和远期生存率，降低死亡率，成为当前亟待解决的关键问题。近年来越来越多的研究显示肠道微生物的分布与恶性肿瘤的发生、发展密切相关，或可成为治疗恶性肿瘤的新辅助方法，特别是嗜黏蛋白阿克曼菌（Akkermansia muciniphila）的报道较多，然而，关于该菌在恶性肿瘤辅助治疗中安全性和有效性的文献报道尚不多见。因此，本文旨在通过收集近年来嗜黏蛋白阿克曼菌在恶性肿瘤方面的文献，将其研究成果和应用结果进行归纳、分析，以期为临床综合治疗提供一定的药物选择。

Abstract:

Malignant tumors are a major global public health problem threatening human health. The combination of multiple therapies, especially targeted therapy combined with immunotherapy, can slow down the progress of malignant tumors and improve the short-term survival rate of the patients. However, these treatment methods cannot cover all patients and have limited long-term efficacy. Therefore, how to improve the quality of life and long-term survival rate and reduce mortality of the patients has become a key problem to be solved. Increasing studies have demonstrated that the distribution of intestinal microorganisms is associated with the occurrence and development of malignant tumors, and regulating intestinal microbiota can serve as a new adjuvant therapy for malignant tumors. Despite the extensive studies about Akkermansia muciniphila in tumor treatment, little is known about the safety and effectiveness of A. muciniphila in the adjuvant treatment of malignant tumors. Therefore, we summarized the research results and application results of A. muciniphila by reviewing the studies on malignant tumors in recent years, aiming to enrich the choices for the comprehensive treatment in clinical practice.